Fisetin vs SS-31 (Elamipretide)
A side-by-side research comparison of Fisetin and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Fisetin | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Fisetin (Senolytic Flavonoid) | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | Dietary compound (research ongoing) | Investigational |
| Mechanism | Acts as a senolytic by tipping senescent cells toward apoptosis (programmed death) while sparing healthy cells. Also has antioxidant and anti-inflammatory activity. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | 286.24 Da | 640.8 Da |
| Half-life | Short; poor baseline absorption (often taken with fat) | 4-6 hours |
| Bioavailability | Low oral; improved with lipids/liposomal forms | High (SubQ) |
| Typical dose | ~20 mg/kg on hit days (protocol-dependent) | 5-40 mg |
| Frequency | Intermittent "hit and run" courses | Daily |
| Route | Oral | Subcutaneous or IV |
Fisetin reported benefits
- Senolytic (clears senescent cells)
- Antioxidant and anti-inflammatory
- Studied for healthspan extension
- Neuroprotective signals in research
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.